InvestorsHub Logo
Followers 2
Posts 438
Boards Moderated 0
Alias Born 03/23/2005

Re: None

Monday, 05/20/2013 2:26:44 PM

Monday, May 20, 2013 2:26:44 PM

Post# of 350
Price target lowered from $16 to $6 by Wedbush:
Wedbush downgraded XenoPort and lowered its price target for shares to $6 from $16 after Arbaclofen Placarbil failed in a Phase III trial for multiple sclerosis spasticity.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.